Westlake Village BioPartners, a venture capital firm, led a $135m Series A round in Latigo Biotherapeutics, a clinical-stage biotechnology company, with participation from 5AM Ventures, Foresite Capital and Corner Ventures. "It is particularly gratifying for me to participate in the evolution of Latigo over the past several years since its inception. With a strong syndicate of investors and the significant capital we've raised, we are well-positioned to build a company that provides new therapeutic options to patients with pain. Latigo's targets are identified by human genetics, grounded in human biology, and characterized using state-of-the-art human model systems. This combination increases our probability of success across the development continuum," Desmond Padhi, Latigo Biotherapeutics Interim CEO.